Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 3Thoracic 2Plasma cell 2Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Multiple Myeloma 10Neoplasms, Plasma Cell 4Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Leukemia 3Breast Neoplasms 3Ovarian Neoplasms 2Myeloproliferative Disorders 2Lymphoma 2Glioblastoma 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Plasma Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

fludarabine phosphate 55Cyclophosphamide 49Peripheral Blood Stem Cell Transplantation 47Mycophenolic Acid 40Tacrolimus 38Whole-Body Irradiation 32Busulfan 27Cyclosporine 25Antilymphocyte Serum 25Methotrexate 21Filgrastim 21fludarabine 19Melphalan 19Radiotherapy 14Methylprednisolone 13Sirolimus 11Flow Cytometry 10Etoposide 10Alemtuzumab 10Cord Blood Stem Cell Transplantation 9Rituximab 8Psychiatric Rehabilitation 8Granulocyte Colony-Stimulating Factor 8Therapeutics 7Polymerase Chain Reaction 7thymoglobulin 6sargramostim 5Prednisone 5Ondansetron 4Immunologic Techniques 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Gemcitabine × Plasma cell × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡